Blog

Positive Phase IV ElectroChemotherapy Clinical Data

2011 has been a resounding success for OncoSec, and 2012 is shaping up to be a pivotal year. Over this last year OncoSec has established a robust clinical development plan based on its novel, first-in-class OMS ElectroImmunotherapy treatment platform for the treatment of rare and deadly skin cancers, including (1) metastatic melanoma; (2) Merkel cell carcinoma; and (3) cutaneous T-cell lymphoma. In conjunction, the company has continued to create value from its advanced-stage OMS ElectroChemotherapy program for the treatment of primary and recurrent localized solid tumors, by analyzing a database of over 400 patients and presenting preliminary results of its Phase I/II breast cancer and preliminary Phase IV skin and head and neck cancer studies.

This year our management has laid out a focused corporate strategy, which was communicated with our shareholders in a recent press release. Complete detail of the Company’s key goals for 2012 can be found using this link.

One of the Company’s goals for 2011 was to increase OncoSec’s visibility in the scientific and investment community. Since our inception in March 2011, we feel that we have achieved this goal, however, it is an effort that we continue to make a priority to ensure that our the urgency of our message of revolutionizing targeted cancer therapy to treat rare and deadly skin cancers is continually voiced for the benefit of those who continue to suffer for these diseases, while still have little treatment options available to them. As a result of our public relations efforts has established a robust social media strategy through Facebook, Twitter and Linkedin, where we hope to reach a broad audience. In addition, OncoSec has been featured in a number of news and journal articles with the most recent being in Drug Discovery News where our President and CEO, Punit Dhillon, contributed an article outlining cutting-edge strategies for the treatment of solid tumors. As 2012 progresses, you can look forward to finding more articles about OncoSec and our revolutionary OMS ElectroOncology therapies.

If you have any questions about OncoSec or our current activities, please contact us at investors@oncosec.com. Thank you for your support

Best,

Punit Dhillon
President & CEO

Why Participate in Social-Digital Now?

Punit Dhillon, President & CEO

Every day over 1,500 people in the US and an estimated 20,000 people around the world, just like you and me, will hear the news that they have been diagnosed with cancer. Thousands of them will be in the indication of melanoma or another lethal form of cancer. Those diagnosed with late stage cancer that has metastasized, or spread to other parts of the body, will have to face the difficult fact that there is less than 50% chance that they will survive more than 5 years with this disease.

With limited treatment options, these patients are in need of solutions now. These are not just statistics; I am constantly reminded of the urgency underlying our effort at OncoSec. We are focusing on developing novel therapies for the treatment of cancer, and to be successful, we are aware that we must be novel in our approach and to take advantage of tools that might not otherwise be traditionally used by companies in our space.

The emergence of digital-based social media has revolutionized our world. Like the Internet in the mid-1990′s and even the telephone and television before that, social media has changed the way we communicate and disseminate information. Today, information is abundant, and people are starved, to not only obtain, but also pass on this information to others. Because of this craving and its convergence with social media, we now think, see and react to events at a speed, and in ways, never before imagined, and this has affected all facets of our life, including health and medicine.

Now, doctors, pharmaceutical companies, advocacy groups, and patients have their own Facebook pages, Twitter accounts and blogs. A patient can post a question on a chat room about their disease and can expect an answer within hours, or even minutes, from a doctor or another patient from the other side of the world. Information fuels innovation, and as a company dedicated to being leaders in innovative ideas to treat cancer, we are obligated to take part in this social media revolution.

As President and CEO of OncoSec, I have the privilege of speaking with the leaders in the field of medical oncology on a daily basis. However, with the advent of social media and it’s complete integration into our daily lives, I realize that, although I have access to the state-of-the-art information as it pertains to medical oncology, it is only the tip of the iceberg. There is more to learn and gain from those waging the war against this terrible disease at the ground level; namely the doctors, patients and family members directly affected by cancer.

So today I join twitter as @PunitDhillon to become a part of the community willing to share their thoughts, insights, stories and beliefs about the urgency to mobilize the community at large to conquer cancer. My purpose is to gain access to the information in the ever-growing social-digital environment with the hope that I can help to build OncoSec into a stronger, more innovative and socially conscious organization.